Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIIL 284 BS in Healthy Volunteers
NCT02273414Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 1999
- Primary completion
- Sep 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) and rheumatoid arthritis (RA) comparing BIIL 284 BS - rising dose with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events, Number of subjects with abnormal changes in laboratory parameters and 2 more. Started Jul 1999; status: completed.
02
Drugs
amelubant
03
Conditions
cystic fibrosis (CF)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02273414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273414.